By applying its high-resolution epitope mapping technology, AAX Biotech will support the development of clinical-stage antibodies to strengthen regulatory submissions and optimize its clinical advancement, the company describes.

Using its Seqitope technology, AAX Biotech will conduct advanced epitope mapping of the humanized monoclonal antibody currently in clinical development as well as related antibodies.

“We are pleased to support our partner in this important phase of their drug candidate’s clinical development,” says Maria L. Knudsen, CEO of AAX Biotech. “With Seqitope, we provide the precision needed to optimize antibody characterization, and we look forward to supporting their continued progress.”